KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease

Core Viewpoint - KeifeRx has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to advance the pre-IND development of KFRX06, a candidate targeting LRRK2 for Parkinson's disease [1] Company Summary - KeifeRx is a privately held biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders [1] - KFRX06 is a preclinical candidate aimed at inhibiting the LRRK2 gene, which is significantly associated with Parkinson's disease [1] Industry Summary - The collaboration with Amneal Pharmaceuticals is intended to support the pre-IND development phase, indicating a strategic partnership to enhance research capabilities in the neurodegenerative disorder space [1]